XML 84 R55.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaborative Arrangements and Licensing Agreements, Bicycle Therapeutics (Details) - Bicycle License Agreement [Member] - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2021
Collaborative Arrangement and Licensing Agreement [Abstract] |  |
Payment of license fee |  | $ 42.0
Trading restriction period under lock up agreement | 1 year |
Equity investment |  | 7.2
R&D expense |  | $ 34.8

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Acquisition of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References No definition available. + Details
Name: | ions_InvestmentInEquitySecuritiesFvNi
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period after completion of initial public offering by an equity investee and restriction to sell equity holding in the investee, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ions_LockUpAgreementTermOfTradingRestriction
Namespace Prefix: | ions_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the cash outflow for payments made under the collaboration agreement for the reimbursement of support received in connection with the Company's Huntington's disease program. + References No definition available. + Details
Name: | ions_PaymentsMadeUnderCollaborationAgreement
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BicycleCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |